Basic Information
| LncRNA/CircRNA Name | GAPLINC |
| Synonyms | NA |
| Region | GRCh38_18:3466250-3478978 |
| Ensemble | ENSG00000266835 |
| Refseq | NR_110429 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot |
| Sample | osteosarcoma tissues,cell lines (MG-63, HOS, SJSA-1, Saos-2, hFOB1.19) |
| Expression Pattern | up-regulated |
| Function Description | GAPLINC expression is elevated in osteosarcoma tissues and cell lines, and correlated with advanced Enneking stage, present distant metastasis, and poor histological grade. Survival analyses indicated that GAPLINC expression was negatively associated with overall survival. |
| Pubmed ID | 30177521 |
| Year | 2018 |
| Title | GAPLINC is a predictor of poor prognosis and regulates cell migration and invasion in osteosarcoma. |
External Links
| Links for GAPLINC | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |